Dr. Richard Solomon, Chief of Nephrology in the Department of Medicine at the University of Vermont College of Medicine and Fletcher Allen Health Care, introduces causes of Contrast-Induced Nephropathy (CIN) in the catheterization lab and its impact on patient outcomes. He became involved with contrast-induced nephropathy (CIN) from a research perspective in the early 1990s, when he designed and conducted the first prospective randomized trial evaluating different therapies for prevention of CIN. CIN, an acute kidney injury resulting from exposure to radiopaque contrast agents during catheterization, possesses long-term risks of systemic adverse events for affected patients. Moreover, CIN bears a significant economic burden. This comes with higher immediate costs stemming from extended hospital stays, intensified patient care, and increased long-term financial responsibilities associated with managing future adverse events. Dr. Solomon outlines the prerequisites for CIN prevention and presents diverse strategies to mitigate its occurrence. Notably, one key aspect in reducing the risk of CIN lies in optimizing contrast delivery. The ACIST CVi® Contrast Delivery System enables precise control over contrast volume and flow rate, surpassing the capabilities of manual hand injectors. This precise control potentially leads to shorter procedures, decreased contrast administration, and the possibility of earlier post-procedural hydration. For further insights into CIN reduction, prevention strategies, and how ACIST CVi® can play a pivotal role in mitigating CIN for patients through optimal contrast delivery, read on.